Improvement in Survival for Patients With Lung Cancer in Taiwan: Implications and Call to Action.

[1]  Chuanhua Yu,et al.  Trends in Deaths Attributable to Smoking in China, Japan, United Kingdom, and United States From 1990 to 2019 , 2022, International Journal of Public Health.

[2]  J. Shih,et al.  Stage Shift Improves Lung Cancer Survival: A Real-world Evidence , 2022, Journal of Thoracic Oncology.

[3]  E. Sokol,et al.  Ancestry-based differences in gene alterations in non–small cell lung cancer: Real-world data using genetic ancestry analysis. , 2022, Journal of Clinical Oncology.

[4]  Jeremy J. W. Chen,et al.  The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan , 2022, Targeted Oncology.

[5]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[6]  J. V. van Meerbeeck,et al.  Implementing Lung Cancer Screening in Europe: Taking a Systems Approach , 2022, JTO clinical and research reports.

[7]  Y. Mitsuishi,et al.  Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? , 2022, BMC cancer.

[8]  H. Welch,et al.  Association of Computed Tomographic Screening Promotion With Lung Cancer Overdiagnosis Among Asian Women , 2022, JAMA internal medicine.

[9]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[10]  J. Borrás,et al.  Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain) , 2021, Scientific Reports.

[11]  F. Cappuzzo,et al.  Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis , 2021, Molecular diagnosis & therapy.

[12]  E. Su,et al.  Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). , 2021 .

[13]  P. Yang.  PS01.02 National Lung Cancer Screening Program in Taiwan: The TALENT Study , 2021 .

[14]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[15]  E. Feuer,et al.  The Effect of Advances in Lung-Cancer Treatment on Population Mortality. , 2020, The New England journal of medicine.

[16]  P. Krawczyk,et al.  Lung Cancer in Poland. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  S. Banerji,et al.  Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. , 2020, Current oncology.

[18]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[19]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[20]  Jing-Yang Huang,et al.  The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients , 2019, Journal of Cancer Research and Clinical Oncology.

[21]  C. Henschke,et al.  Landscape on CT screening for lung cancer in Asia , 2019, Lung Cancer.

[22]  Eric A. Miller,et al.  Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team 1. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  J. Brodersen,et al.  Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening: A Secondary Analysis of the Danish Lung Cancer Screening Trial , 2018, JAMA internal medicine.

[24]  B. Møller,et al.  Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. , 2018, Lung cancer.

[25]  F. Bray,et al.  Lung cancer incidence trends in Uruguay 1990-2014: An age-period-cohort analysis. , 2018, Cancer epidemiology.

[26]  W. Olszewski,et al.  NSCLC molecular testing in Central and Eastern European countries , 2018, BMC Cancer.

[27]  Y. Qiao,et al.  [China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)]. , 2018, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[28]  Eugenio Paci,et al.  Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial , 2017, Thorax.

[29]  P. V. van Ooijen,et al.  Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. , 2016, The Lancet. Oncology.

[30]  M. Tonelli,et al.  Recommendations on screening for lung cancer , 2016, Canadian Medical Association Journal.

[31]  P. Krawczyk,et al.  Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  N J Wald,et al.  UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening , 2015, Thorax.

[33]  K. Balakrishnan,et al.  Respiratory risks from household air pollution in low and middle income countries. , 2014, The Lancet. Respiratory medicine.

[34]  D. R. Lewis,et al.  US lung cancer trends by histologic type , 2014, Cancer.

[35]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[36]  Jan P van Meerbeeck,et al.  Small-cell lung cancer , 1980, The Lancet.

[37]  G. Byrnes,et al.  Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.